bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD

bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript

BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?

bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering

bioAffinity Technologies Announces Closing of $3.2 Million Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering

bioAffinity Technologies Announces Pricing of $3.2 Million Offering

bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript

bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans